Notification of Record Date for the Annual General Meeting and Extraordinary General Meeting
June 12 2008 - 11:46AM
PR Newswire (US)
VALLEY COTTAGE, New York, June 12 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) today announced
that the record date for its Annual General Meeting and
Extraordinary General Meeting (collectively, the "Meetings")
scheduled for July 17, 2008, is hereby amended so that shareholders
of record at the close of business on June 12, 2008 are entitled to
notice of, and to vote at the Meetings. All shareholders are
cordially invited to attend the Meetings in person. ADR holders
shall receive a proxy with the relevant voting instructions
regarding voting at such Meetings. The Notice of the Meetings is
available for the public at the US Securities Exchange Edgar site:
http://www.sec.gov/ and at the Israel Securities Authority's site:
http://www.magna.isa.gov.il/. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of diabetic neuropathic pain and
HCV. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of diabetic neuropathic pain,
which is currently in a Phase 2b study. XTL has out-licensed its
novel pre-clinical HCV small molecule inhibitor program. XTL also
has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly
traded on the NASDAQ and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd.
CONTACT: Ron Bentsur, Chief Executive Officer, XTL
Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024